Danuglutide vs Lixisenatide

Danuglutide is an experimental GLP-1 receptor agonist that has not yet been approved by the FDA for any use, while Lixisenatide is an FDA-approved GLP-1 receptor agonist sold under the brand names Adlyxin and Soliqua, and is approved to treat type 2 diabetes. Both drugs work the same way by mimicking a natural gut hormone, but Danuglutide is still in development and not available for patients, whereas Lixisenatide is already on the market.

AI summary of the sources below.